Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix

Myovant Sciences has initiated a phase 3 clinical program consisting of two international clinical trials to evaluate the efficacy and safety of relugolix in women with endometriosis-associated pain.

Relugolix is an oral, once-daily, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist that decreases estrogen and progesterone. Relugolix will be evaluated with and without low-dose hormonal add-back therapy. “Endometriosis is a very common and debilitating estrogen-driven disease that occurs in around 10% of pre-menopausal women,” said Linda Giudice, a reproductive endocrinologist at the University of California, San Francisco School of Medicine. “Women with moderate to severe endometriosis-associated pain are in great need of well-tolerated medicines to help ease their pain and provide a treatment alternative to invasive procedures such as laparoscopy and hysterectomy.”

By Bryan Smith